Opioid-Induced Constipation in Advanced Illness: Safety and Efficacy of Methylnaltrexone Bromide by Bader, S. et al.
Clinical Medicine Insights: Oncology 2011:5 201–211
doi: 10.4137/CMO.S4867
This article is available from http://www.la-press.com.
© the author(s), publisher and licensee Libertas Academica Ltd.
This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Open Access
Full open access to this and 
thousands of other papers at 
http://www.la-press.com.
Clinical Medicine Insights: Oncology
RevIew
Clinical Medicine Insights: Oncology 2011:5  201
Opioid-Induced constipation in Advanced Illness:  
Safety and Efficacy of Methylnaltrexone Bromide
S. Bader, K. Jaroslawski, H.e. Blum and G. Becker
Department of Palliative Care, University Hospital Freiburg, Robert-Koch-Str. 3, D-79106, Freiburg. 
Corresponding author email: sabine.bader@uniklinik-freiburg.de
Abstract: Constipation, one of the major side effects of opiates used in palliative care, can impair patients’ quality of life to a point 
where it prevents sufficient pain control. Methylnaltrexone is a novel μ-receptor antagonist, which does not pass the blood brain barrier. 
It is licensed to treat opiate induced constipation for patients with advanced diseases. This review article presents an overview of phar-
macology and safety of its application, evidence of its efficacy and economic aspects of its use in clinical practice. Available data are 
limited but strongly suggest that methylnaltrexone causes laxation in less than 24 hours for at least half of those patients over the first 
two weeks of usage without impairing pain control or causing serious adverse effects. To avoid danger of gastrointestinal perforation 
it is contraindicated for patients at risk for that complication. More research is needed to evaluate its long-term efficacy and economic 
impact.
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Introduction
Opiates are among the most commonly prescribed 
drugs  for  patients  with  advanced  illness  to  treat 
pain and dyspnea. Unlike for nausea and sedation, 
patients  develop  no  tolerance  for  opioid-induced 
bowel    dysfunction  and  constipation.  They  are  the 
clinical symptoms of different effects of opioids and 
  opiates mainly on µ-receptors in the gut, occurring 
in  up  to  90%  of  those  patients.1–3  Gastrointestinal 
reflux, incomplete evacuation, hard stool,   abdominal 
  distension, bloating and discomfort by accumulation 
of gas and secretions can lead to vomiting, nausea, 
anorexia  and  interference  with  the  administration 
or  absorption  of  medication.4  These  debilitating 
  symptoms can   seriously impair patients’ quality of 
life comparable even to pain, up to a point where 
some prefer inadequate pain control to avoid these 
side effects.3,5
Commonly, opiate induced constipation (OIC) is 
treated nonspecifically with stool softeners, osmotic 
agents and stimulant laxatives. These don’t always 
succeed and they are sometimes not very comfort-
able to take, especially for very sick patients.2 The 
evidence of their efficacy is sparse, mostly because 
of the lack of adequate clinical trials in that field.6 
  Recommendations  rely  on  expert  opinions  and 
  common experience.6,7 There is an urgent need for 
more research and development of additional, ideally 
more specific and effective treatments for this bur-
densome problem.
The neuronal net of the gut comprises the   largest 
and most complicated conglomeration of nerves in 
the body after the brain and almost every   cerebral 
transmitter  or  neurohormone  with    corresponding 
receptors  can  be  detected  there.  According  to 
  neuroanatomical and neurophysiological studies in 
animals,  OIC  is  largely  mediated  by  µ-receptors 
located in the   myenteric plexus of the   gastrointestinal 
tract.8,9 Enkephalins, endorphins and dynorphins are 
their physiological agonists and their activation by 
exogenous opiates causes a decrease in propulsive 
motor  activity  and  an  increase  of  netto  intestinal 
fluid absorption.9–11 Blocking µ-receptors by antag-
onists like naloxone and naltrexone reverses OIC 
but also antagonizes the opioid’s analgetic effect, 
which is largely caused by centrally located opioid 
receptors. 
Lately, two opiate receptor antagonists have been 
developed with restriction of effect to the periphery 
by  their  pharmacokinetic  behavior.12,13  Alvimopan 
has been approved in the US by the FDA for the inpa-
tient treatment of postoperative ileus in 2008 but the 
approval is restricted to eight days as it has been asso-
ciated with myocardial events in studies for long-term 
use for opiate-induced constipation.
Methylnaltrexone is a quaternary ammonium deri-
vate of naltrexone with higher polarity, lower lipid 
solubility and therefore less ability to pass the blood 
brain barrier.14 This restriction of its clinical effect to 
the  periphery  renders  methylnaltrexone the  perfect 
drug against mainly peripherally mediated OIC.10,15 
For  twenty  years  its  efficacy  in  humans  has  been 
researched  and  lately  several  phase  III  studies  on 
patients with opiate induced constipation have been 
performed with promising results.
Progenics owns the exclusive worldwide rights for 
methylnaltrexone. In collaboration with Wyeth since 
2005, the drug has been licensed for OIC and approved 
by the FDA (April 2008) and the EMEA (July 2008) 
for patients with advanced diseases whose treatment 
of OIC with conventional laxatives has failed.
This article aims to give a short overview of the 
pharmacological characteristics of methylnaltrexone. It 
reviews and critically appraises the evidence of its use 
concerning clinical efficacy, safety and economic value 
for the treatment of patients with advanced illness. The 
literature search strategy is described in Table 1.
Pharmacology
Pharmacokinetics
Methylnaltrexone, a quaternary methylated   ammonium 
derivate from naltrexone (Fig. 1), has shown effective-
ness in preclinical studies on humans as oral, subcu-
taneous  and  intravenous  application.16  Its  polarity 
leads to a low intestinal absorption rate and prevents 
the   passage of the blood brain barrier in therapeutic 
  dosages. As subcutaneous application, the plasma con-
centration peaks after about half an hour. The drug has 
a half-life of about eight hours. About half of it is elimi-
nated unchanged through the kidneys and another 40% 
fecally.17,18 High clearance and therefore low biologi-
cal half-life lead to a low accumulation rate. This has 
been clinically confirmed in a study where intravenous 
methylnaltrexone has been given to healthy subjects Safety and efficacy of methylnaltrexone bromide
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repeatedly every six hours twelve times in a row with 
no significant change in area under curve between the 
first and last application19 (Table 2).
Only about ten percent of the substance is metabo-
lized by glucuronidation in the liver and no signifi-
cant  interference  with  the  cytochrome  system  has 
been noticed. According to the prescribing informa-
tion there is no data available on patients with severe 
hepatic impairment, nor on patients with end stage 
renal disease requiring dialysis. Below a creatinine 
clearance of 30 ml/min, a dose-reduction of half is 
recommended by the distributor.
Pharmacodynamics
The restriction of the clinical effect to the   periphery 
is  only  due  to  its  pharmacokinetics  (Fig.  2). 
  Intracerebrally  applied  methylnaltrexone  causes 
antagonism of the mainly centrally mediated analgetic 
effect  of  morphium  showing  its  affinity  to  central 
µ-receptors as well.20 Methylnaltrexone antagonizes 
morphium with a medium inhibitory concentration of 
75 nm (IC50 75 nm) at the µ-receptor and an exceed-
ingly higher one at the k-receptor (IC50 575 nm). 
It has negligible affinity to d-receptors. Opiates and 
opioids cause a decrease in acetylcholine release in 
myenteric neurons leading to a reduction of propul-
sive motility of the smooth muscles in the gut, an 
increase in sphincter tonus on pylorus and anus and 
an  increase  in  fluid  absorption. Antagonizing  their 
effect shortens the time of transfer and increases the 
water content of stool.21
studies
Preclinical Trials
Phase I and II studies on a small number of healthy 
volunteers showed efficacy of different applications of 
methylnaltrexone antagonizing opiate induced effects 
on the gut, such as the deceleration of gastric emptying 
or of prolongation of oral-cecal transit time induced 
by intravenous morphine16,22 (Table 3). Similar results 
were obtained in phase II studies on chronic metha-
done users. All 22 patients on   methadone experienced 
fast laxation without any signs of opioid withdrawal 
by the treatment.23 The effective dosages used did 
not  evoke  clinically  apparent  adverse  effects  in 
these homogeneous groups of subjects in controlled 
  settings. Even if the validity of these results for the 
more complex group of patients in a palliative care 
situation is low, they opened the path for clinical   trials 
on these patients by repeatedly showing a high rate of 
Table 1. Search strategy for literature retrieval.
we performed a literature search using OvID’s interface of the following databases: OvID MeDLINe, including Medline  
in Process and other non indexed citations (1950–2011), Cochrane Database of Systematic Reviews (4. Quarter 2010),  
Cochrane Central Register of Controlled Trials (4. Quarter 2010), BIOSIS Previews (1969–2011). The databases were  
searched for articles identified by the terms ‘methylnaltrexone’, for articles with the terms ‘constipation’, ‘intestinal 
obstruction’ and for articles retrieved by the terms ‘opiate’, ‘side effect’ and by ‘palliative care’. The results were combined 
and limited to clinical trials, humans only. In addition, searches were performed in NLM’s PubMed (1966–2011) and on 
the internet using science-specific search engines Scirus and Google Scholar with the search terms ‘Methylnaltrexone’, 
‘constipation’, ‘intestinal obstruction’, and ‘opiate’, ‘side effects’, ‘palliative care’ and related terms. For identifying further 
trials we went to several trial registers, including Current Controlled Trials Ltd., (http://www.controlled-trials.com), world 
Health Organisation International Clinical Trials Registry Platform ICTRP (http://www.who.int/trialsearch), National 
Institutes of Health Randomized Trial Records (http://clinicaltrials.gov) and Pharmaceutical Industry Clinical Trials 
Database, initiated by the Association of the British Pharmaceutical Industry (http://www.abpi.org.uk). Last date of search 
was in March 2011. In addition, reference lists of articles retrieved were screened for relevant publications.
Modified from Deibert 2010.29
O O HO
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Figure 1. Biochemical structure of Methylnaltrexone.Bader et al
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efficacy and a low toxicity profile in this small group 
of healthy humans.
Phase III, Clinical Trials
Since 2008, three randomized controlled trials (RCTs) 
about the use of methylnaltrexone in the target popu-
lation of palliative care patients with suspected OIC 
in clinically realistic settings were fully published. 
These led to the approval of the drug in 2008 by FDA 
and EMEA (Table 3). Later on, a meta-analysis of 
data on 288 patients from those trials was performed 
for a Cochrane review.6
To  assess  the  potentially  most  effective  and  safe 
dosage of methylnaltrexone in this patient   population, 
Table 2. Pharmacology of methylnaltrexone (parameters after repeated intravenous application, healthy volunteers).
Chemistry Derivative of naltrexone; molecular weight 436.3 Da; positively charged
Receptor antagonism Peripheral µ-opioid receptor antagonist; 8-fold lower potency at k-opioid 
receptor; 120-fold lower potency at δ-opioid receptor
Route Intravenous, subcutaneous, and oral (including enteric-coated)
Cmax (ng/mL) 675 (SD 495–855) (0.3 mg/kg)
tmax (h) 0.10 (SD 0.05–1.15) (0.3 mg/kg)
AUC (ng/h*mL) 353 (SD 262–444) (0.3 mg/kg)
t1/2 (h) 2.9 (SD 2.0–3.8) (0.3 mg/kg)
Metabolism Small percentage undergoes hepatic metabolism (possibly glucuronidation)
Active metabolite None
elimination 40%–50% renal and unchanged, another 50% fecal elimination
Modified from Becker.12,13,17–19,30
Opiate effect in the cerebrum 
mediated by the µ-receptor
• Pain reduction
• Reduced perception of dyspnea
• Nausea
• Sedation
µ-
receptor
blocked
µ-
receptor
blocked
µ-
receptor
blocked
µ
receptor
active
µ
receptor
active
Naltrexone
Opioid withdrawal
Reduction of analgesia
Methylnaltrexone
does not pass Blood-Brain-Barrier
Brain
Opiate effect on gut motilty
through activated µ-receptor
• Reduction of propulsive motility of the
   smooth muscle and increase in sphincter
   tonus on pylorus and anus
• Inhibiton of acetylcholine release in
  myenteric  plexus
• Increased fluid absorption
• Increased time of stool transfer
• Decreased water content of stool
Naltrexone
Methyl-
naltrexone
Gut
Inhibition of
gastrointestinal
adverse effects of
opioids
Figure 2. Opiate effects in brain and gut inhibited by Naltrexone and Methylnaltrexone which cannot pass the blood-brain-barrier because of its chemical 
structure.Safety and efficacy of methylnaltrexone bromide
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Table 3. Trials on humans.
Author Design n Intervention Results
Yuan
1996
Phase I/II,  
randomised,  
double-blind, crossover  
placebo-controlled
12 healthy  
volunteers
1. Group: intravenous placebo,
2.   Group: placebo plus  
0.05 mg/kg morphine
3.   Group: 0.45 mg/kg  
methylnaltrexone  
plus 0.05 mg/kg morphine.
Morphine significantly  
increased oral-cecal transit  
time from 104.6 +/- 31.1  
minutes (mean +/- SD) 
 to 163.3 +/- 39.8 minutes  
(P , 0.01).
Methylnaltrexone prevented  
97% of morphine-induced  
increase in oral-cecal  
transit time
Murphy
1997
Phase I/II,  
randomised,  
double-blind, crossover  
placebo-controlled
11 healthy  
volunteers
1. Group: placebo (saline),
2. Group: 0.09 mg/kg morphine
3.   Group: 0.09 mg/kg  
morphine plus 0.3 mg/kg 
methylnaltrexone
Methylnaltrexone given  
concomitantly with morphine  
reverses almost completely  
the morphine-induced delay  
in gastric emptying
Yuan
1997
Phase II,  
non-randomised,  
single-blind  
dose-escalation
14 healthy  
volunteers
Descending doses of oral  
Methylnaltrexone  
(from 19.2 mg/kg) with
6.4 mg/kg oral methylnaltrexone   
significantly attenuated the  
morphine-induced delay  
in oral-cecal transit time  
dose-dependent response  
was obtained.
Yuan
1997
Phase II,  
non-randomised,  
single-blind  
dose-escalation
14 healthy  
volunteers
Ascending doses of oral  
methylnaltrexone 
(0.64, 6.4, 19.2 mg/kg/KG)
Safe and well tolerated  
up to maximum dose
Yuan
1997
Phase II,  
randomized,  
double-blind,  
placebo-controlled
14 healthy  
volunteers
1.   Group group single-blind oral  
placebo and intravenous  
placebo
2.   Group: oral placebo  
and intravenous morphine 
(0.05 mg/kg) or
3.   Group: oral methylnaltrexone  
(19.2 mg/kg) and intravenous  
morphine (0.05 mg/kg).
Oral methylnaltrexone  
(19.2 mg/kg) completely  
prevented morphine-induced  
increase in oral-cecal  
transit time
Yuan
2000
Phase II,  
randomised,  
double-blind,  
placebo-controlled
22 methadone  
users
1. Placebo; group
2.   0.015–0.365 mg/kg Mntx all 
intravenously; 
Both groups tested  
on days1 and 2
Decrease from baseline  
in oral-cecal transit time  
(min, mean [SD]):
Group 1: 1.4 (12);
Group 2: 77.7 (37.2)  
(P , 0.01 vs. group 1);
no laxation with group  
1 vs. laxation for all 
of group 2 (P , 0.01); 
no opioid withdrawal symptoms
Yuan
2000
Phase II,  
single-blind,  
dose ranging
12 methadone  
users
Placebo followed next day with:
Group 1: 0.3 mg/kg Mntx
Group 2: 1.0 mg/kg Mntx
Group 3: 3.0 mg/kg Mntx  
all orally
Time to bowel movement  
(h, mean [SD]):
Group 1 (results for 3 of  
4 patients): 18.0 (8.7);
Group 2 (4 of 4 patients):  
12.3 (8.7);
Group 3 (4 of 4 patients):  
5.2 (4.5); Dose-response  
effect with drug, P = 0.04;
no adverse effects; no opioid  
withdrawal symptoms
(Continued)Bader et al
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Table 3. (Continued)
Author Design n Intervention Results
Portenoy
2008
Phase III,  
double-blind,  
randomized,  
parallel-group,  
repeated dose,  
dose-ranging
33 patients  
in palliative  
care
1. Group 1 mg sc Mntx
2. Group 5 mg sc Mntx
3. Group 12.5 mg sc Mntx
4. Group 20 mg sc Mntx
Laxation response in first  
four hours:
1. 10% (n = 10)
2. 43% (n = 7)
3. 60% (n = 10)
4. 33% (n = 6)
Thomas
2008
Phase III  
randomized,  
double-blind  
placebo-controlled,  
clinical trial
133 patients  
in palliative  
care
1. Placebo
2.   Group 0.15 mg sc Mntx 
repeated day 3,5,7,9,11,13
Laxation response in first four  
hours after first injection:
1. 15%
2. 48%
Laxation response in first four  
hours for each of the following  
injection:
1. 9, 13, 7, 14, 10, 8%
2. 46, 47, 38, 41, 37, 38%
More patients in MNTX  
group than with placebo  
had: improvement of stool  
consistency and bowel status
Reduction of difficulty  
of laxation and distress  
associated with constipation
Slatkin
2009
Phase III  
randomized,  
double-blind  
placebo-controlled,  
clinical trial
154 patients  
in palliative  
care
1. Placebo
2. Group: 0.15 mg sc Mntx
3. Group: 0.3 mg sc Mntx
Laxation response in first  
four hours:
1.14% (95% CI: 4%–23%)
2.62% (95% CI: 48%–76%)
3.58% (95% CI: 75%–71%)
Modified from Becker.12,13
Portenoy et al performed a one week long double-blinded 
study in which they randomly assigned 33 patients on 
stable opiate medication with defined criteria of consti-
pation to receive either 1 mg, 5 mg, 12.5 mg or 20 mg of 
  methylnaltrexone subcutaneously three times in a row 
every second day.24 This was followed by the option 
of an open label treatment with an initial dose of 5 mg 
subcutaneously, which could be adjusted in a range of 
2.5 mg to 20 mg by the investigator based on patient 
response. The primary outcome had been defined as 
having at least one rescue free bowel movement within 
four hours after the initial dose. While only 10% of 
the patients with 1 mg reported a laxation through this 
period, 48% of all patients receiving any higher dosage 
achieved  that  goal  without  any  significant  difference 
between those three groups. This indicates, that there is 
no additional effect above a certain dosage of the drug.
In  the  following  elegantly  designed  open  label 
phase, where the dose could be adjusted to the patient 
response, 49%–63% of all patients reached the pri-
mary outcome, while most injections (95 of 100) were 
between 5 and 12.5 mg. Only four required 15 mg and 
one got decreased to 1 mg to achieve laxation dur-
ing the following four hours. Concurring with this, a 
dosage of 5 mg of Methylnaltrexone seems to be the 
minimum effective dose. Further increase of dosage 
would not add any benefit to the effect, again suggest-
ing a ceiling effect concerning the efficacy of the drug. 
Considering that the average weight of the patients 
under study was about 64 kg, the dose for optimal 
treatment would range between 0.08 and 0.20 mg/kg.
Based on these results, Thomas et al performed 
a multi-center trial where 133 patients with similar 
inclusion criteria as in the last trial were random-
ized to receive either placebo or 0.15 mg/kg meth-
ylnaltrexone subcutaneously every other day for two 
weeks. They allowed dose escalation (0.3 mg/kg or 
twice  as  much  volume  of  placebo)  on  the  second 
week according to patient response.25 Again 48% in 
the verum group versus 15% in the placebo group 
had a rescue free laxation during the first four hours 
after initial treatment. Significantly more patients in Safety and efficacy of methylnaltrexone bromide
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the verum group had a rescue-free laxation during 
the first four hours after two or more of the first four 
  dosages than patients receiving placebo. The median 
time  to  the  first  bowel  movement  of  the  verum 
patients, who achieved a laxation within the first four 
hours,  was  about  30  minutes. This  correlates with 
Tmax  of  subcutaneously  applied  methylnaltrexone 
in   pharmacokinetic trials on humans.17 The median 
time to laxation after first dose for all patients was 
6.3 hours in the verum and more than 48 hours in the 
placebo group. No difference in pain or opiate with-
drawal scores at baseline and each evaluation was 
found between verum and placebo group. Of adverse 
effects  occurring  in  more  than  5%  of  all  patients, 
abdominal pain, flatulence, nausea, increased body 
temperature and dizziness had a 3% higher incidence 
in the verum group. This was not significant though. 
Unlike in the placebo group, the majority of patients 
in the verum group perceived their bowel status as 
improved.  In  both  groups  patients  who  achieved 
  laxation within the first four hours after the injection 
reported softer stool consistency. More patients in the 
verum group sensed a decrease of distress associated 
with constipation and difficulty of laxation.
Similar results showed the study of Slatkin et al, 
who  randomly  assigned  a  clinically  comparable 
group of 154 patients to the double-blinded applica-
tion of a single dose of either placebo, 0.15 mg/kg 
or  0.3  mg/kg  methylnaltrexone.26  The  percentage 
of  patients  defecating  within  the  first  four  hours 
after  injection  was  13.5%  (95%  CI  4.2%–22.7%) 
for    placebo,  61.7%  (95%  CI  47.8%-75.6%)  for 
Table 4. Executive summary.
Clinical problem • Opiates induce constipation in up to 90% of cancer patients
• Limited efficacy of conventional laxatives
Mechanism of action • Methylnaltrexone blocks µ-receptors in the gut
• Counteracts opiate-induced decrease of ACh-release on neurons
• Increased propulsary muscle activity in the gut
• Softer stool by reducing the water absorption
Pharmacokinetics • effect limited to the periphery, too polar to pass blood-brain barrier
• Tmax 0.5 h
• T1/2 = 8 h
• No active metabolites in humans
• Only 10% hepatic glucuronidation
• 40% fecal, 50% renal elimination
Clinical efficacy for palliative care •   Significantly higher rate of rescue free laxation in the first 4 and 24 hours  
after administration of the drug compared to placebo
• About half of the patients achieve laxation within four hours
• No sufficient data on long and medium term efficacy (.2 weeks)
Safety and tolerability • Toxity studies show high LD50 dose in animals
• No accumulation on repeated doses
• 50% Dose reduction if creatinine clearance less than 30 ml/min
• Mild averse effects (abd. pain, flatulence, dizziness, hypotension)
• No reduction of pain control
• No signs of opiate withdrawal
• Contraindicated for patients at risk for gut perforation
• No sufficient data on long and medium term usage
Dosage and administration • 8 mg sc. every other day for a body weight between 38 to 62 kg
•12 mg sc. every other day for a body weight of 63 to 114 kg
• 50% dose reduction if creatinine clearance less than 30 ml/min
License FDA and eMeA approval since 2008 for patients with advanced  
diseases if OIC not successfully treated with conventional laxatives
Patients preference Limited data with no statistical significance on quality of life scores 
suggests that more patients on methylnaltrexone experience an 
improvement in difficulty of laxation and bowel status and a decrease in 
distress associated with constipation compared to patients on placebo
economic aspects Further research neededBader et al
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0.15 mg/kg and 58.2% (95% CI 45.1%–71.2%) for 
0.3 mg/kg methylnaltrexone. The median time for all 
patients to rescue free laxation was 1.1 h, 0.8 h and 
over 24 h for the 0.15 mg/kg, the 0.3 mg/kg and the 
placebo group respectively. 147 patients took part in 
a subsequent three-month open-label phase and again 
more than 50% of all of those patients achieved a 
rescue-free laxation within four hours after the first 
open-label dose. No difference in pain or withdrawal 
scores between the three groups and compared to the 
baseline data was reported. The incidence of adverse 
effects was higher in the verum than in the placebo 
group for mild or moderate abdominal pain, flatu-
lence, nausea and dizziness. Severe adverse effects 
possibly  related  to  methylnaltrexone  were  only 
reported in mostly one to three cases per symptom 
and comprised increased sweating (3) and pain (2), 
burning at injection site, vomiting, diarrhea, asthenia, 
increased blood   pressure, severe   dehydration, mus-
cular cramp, loss of   consciousness, tremor, delirium, 
hallucination,   dyspnea and flushing.
In  a  meta-analysis  of  the  data  from  patients 
of  Thomas’  and  Slatkin’s  trials,  the  Odds  Ratio 
  concerning  the  outcome  of  rescue  free  laxation 
within four hours after injection of methylnaltrexone 
versus placebo was 6.95 (95% CI: 3.83 to 12.61), 
and within 24 hours it was 5.42 (95% CI: 3.12 to 
9.42). The   quality of evidence for this outcome in 
the attending Cochrane review was rated as moder-
ate (three points out of four). Only two studies with 
positive    outcome  published  for  this  intervention 
cannot  rule  out    publication  bias. Allocation  con-
cealment, selective reporting and other biases could 
also not be excluded by the presentations of all three 
trials. In Portenoy’s trial   incomplete outcome data 
weren’t addressed.6
All three multi-centered studies mentioned above, 
recruited  patients  from  and  were  conducted  in 
  several  different  palliative  care  settings  (Hospices, 
  palliative care centers and nursing homes). They all 
had similar and primarily well-defined inclusion and 
exclusion  criteria  considering  age,  type  of  disease 
(including ca. 15%–40% non cancer), life expectancy 
(at least one month to six months), definition of con-
stipation and stability of treatment with opiates and 
laxatives   during trial precedent days.
How patients had been approached has not been 
described  in  any  publication,  which  leaves  some 
danger of selection bias, but baseline characteristics 
of the studied patients were presented to allow for a 
judgment about the validity of the trial for a palliative 
care setting concerning the study   population. Typical 
for trials in palliative care, there was a relatively high 
attrition rate, which was addressed by intention to 
treat analysis and reasons for attrition were reported. 
None of the studies provided full information about 
the  reasons  why  some  participants  withdrew  “by 
own request”.
The  use  of  additional  laxatives  before  and 
  during the trials was not precisely reported, neither 
in   quantity nor in quality, and can therefore not be 
rated as optimal. No study has been done yet to com-
pare   methylnaltrexone to intensifying or optimising 
  conservative treatment.
As abstract only, and therefore only   rudimentarily 
evaluable in a review, Karver et al reported 124   cancer 
patients with a life expectancy of 1–6 months receiving 
either placebo, methylnaltrexone 0.15 mg/kg or meth-
ylnaltrexone 0.3 mg/kg subcutaneously.   Rescue-free 
laxation within 4 hours after a single dose of the study 
drug achieved 59.5% of the patients receiving meth-
ylnaltrexone 0.15 mg/kg and 55.6% of the ones on 
0.3 mg/kg versus only 16.7% of the placebo group. 
The  same  abstract  also  reported  78  other  patients 
receiving 0.15 mg/kg or placebo over two weeks every 
second day with similar results. There also was no 
reporting of reduction of pain control or symptoms of 
withdrawal.27
safety
The  main  side  effects  of  methylnaltrexone  in  the 
  studies  mentioned  above  were  mostly  abdominal 
cramps and flatulence, which appear to be linked to 
the intentional propulsive effect on the gut.   During 
the  first  eighteen  months  since  methylnaltrexone 
had been licensed, this drug has been prescribed to 
about 6900 patients in the USA. Seven patients have 
been reported to the FDA, who experienced bowel 
  perforation  during  two  days  after  the  application, 
most of them with an underlying disease of the gut.28 
  Therefore extreme caution is recommended in the 
usage of the drug for patients at risk for   gastrointestinal 
perforation or mechanical ileus by tumor infiltration, 
inflammation of the bowel wall or treatment with 
steroids,  non-  steroidal    anti-  inflammatory  drugs  or 
bevacizumab.Safety and efficacy of methylnaltrexone bromide
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Ascending doses of methylnaltrexone were intra-
venously  applied  to  healthy  male  volunteers.  The 
dose-limiting adverse effect of methylnaltrexone was 
orthostatic hypotension at 0.64 mg/kg or 1.25 mg/kg, 
which was transient and self-limiting. No such effects 
were observed at a dosage of 0.32 mg/kg. Plasma 
levels of methylnaltrexone in excess of 1.400 ng/mL 
were associated with orthostatic hypotension, a rare 
side effect in clinical studies later on. No significant 
subjective changes, release of histamine or changes 
in physical examination or laboratory studies   during 
the  course  of  the  study  were  observed    indicating 
that methylnaltrexone is well tolerated at doses of 
0.32 mg/kg and less in healthy humans.18
Repeated  administration  of  intravenous  meth-
ylnaltrexone every six hours twelve times in a row 
was  well  tolerated  in  humans  with  no  significant 
adverse events or clinically noteworthy alterations in 
pharmacokinetics.19
Methylnaltrexone can block nicotinic   ganglionic 
and  cardiac  muscarinic  receptors  by  inhibiting  the 
acetylcholine release which might be the mechanism 
of  orthostatic  hypotension  on  moderate  to  higher 
dosages and could have a potentially fatal effect.20 
Acute animal toxicity studies showed a high LD50 
of 100 mg/kgKG intraperitoneally in rats. In   primates 
up to 50 mg/kgKG (iv, sc, im) have been tolerated 
which  is  far  beyond  the  recommended  dose  for 
treatment of 0.15 mg/kgKG. Unlike rats and mice, 
humans  and  dogs  cannot  demethylate  methylnal-
trexone to naltrexone in a clinically relevant quantity 
and even at doses of 10–50 mg/kgKG in dogs and 
monkeys,  methylnaltrexone  did  not  penetrate  into 
the brain. Central effects like the depression of the 
breathing reflex are therefore not to be expected when 
  peripherally applied.14,15
Economic Aspects
In palliative care, where overall survival is not a valid 
outcome to judge treatment, quality of life parameters 
are used to evaluate interventions. This has not been 
done rigorously enough in the trials mentioned above. 
They were designed to prove the effect of methylna-
trexone on laxation as the primary endpoint. Data on 
quality of life scores from those trials suggests that 
once methylnaltrexone induces laxation it decreases 
patients’  distress  related  to  constipation. This  data 
did not all reach statistical significance.25,26 Therefore 
future trials have to focus more on the systematical 
assessment of quality of life aspects for convincing 
results to support the introduction of this relatively 
expensive intervention.
Earnshaw  has  published  a  model-based  cost-
  effectiveness analysis based on data from the random-
ized  controlled  trials  mentioned  above.31  Resource 
use, costs (adjusted for the Netherlands), utilities and 
mortality  were  obtained  from  published  literature 
and  supplemented  with  data  from  clinical  experts. 
The analysis assigned an incremental cost per qual-
ity adjusted life year (QALY) of €40,865 and costs 
per constipation-free day of €25.92 to the additional 
treatment of opiate induced constipation with meth-
ylnaltrexone  on  top  of  standard  care  at  an  hourly 
nurse cost of about €65. Even if this kind of analysis 
is extremely sensitive to bias as it is based on assump-
tions,  which  can  only  marginally  be  assessed  by 
sensitivity analysis, those numbers can give an idea 
about the   potential economic impact of a treatment. 
Further research is needed to explore this subject in 
different health care settings to allow for satisfying 
judgement.
Discussion
Constipation as one of the major side effects of opi-
ates used in palliative care can impair patients’ qual-
ity of life to a point where it prevents sufficient pain 
control.  Conventional  laxative  therapies  are  some-
times not satisfactory and there is a lack of evidence 
on their efficacy.
Despite the limitation to only three fully published 
double-blinded  randomized  phase  III  trials,  where 
potentially  biasing  flaws  cannot  entirely  be  ruled 
out, due to the way they are presented, the evidence 
through data available strongly suggests an efficacy 
of methylnaltrexone in causing laxation within four 
and up to 24 hours after its subcutaneous application 
for at least half of these patients compared to placebo 
during at least the first two weeks of use.
The reason why only about half of the patients 
react remains unclear and has to be subject to further 
research.  Constipation  in  those  patients  might  not 
  primarily be caused by opiates at the gut but by other 
concomitant factors or by centrally mediated opiate 
effects.
The drug is safe to apply with only minor side 
effects in therapeutic dosage with a high therapeutic Bader et al
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ratio in animal studies, no tendency to accumulate, 
low metabolism and therefore in theory little danger 
of pharmacokinetic drug interaction. This can only 
be  concluded  from  small  phase  I-  and  II-studies. 
Only severe impairment of renal function affects its 
elimination. A dose reduction of half is required if 
the creatinine clearance is less than 30 ml/min. The 
drug requires a minimum dose for effect of about 
0.15 mg/kg sc. and the dose-impact relation seems 
to have a ceiling effect with no further increase in 
potency after 0.3 mg/kg sc.
Patients receiving melthylnaltrexone experienced 
mild  flatulence  and  dizziness  insignificantly  more 
often than patients on placebo. There were reports of 
gut perforation, which might have been related to this 
medication; because methylnaltrexone’s mechanism 
of action involves an increase of propulsive smooth 
muscle activity in the gut, patients at risk for ileus or 
perforation, as well as patients with signs of peritoneal 
carcinosis or catheters inserted into the peritoneum 
had been excluded of the trials. Methylnaltrexone is 
strictly contraindicated for patients under that risk. 
Few  cases  where  methylnaltrexone  was  associated 
with gut perforation have been reported to the adverse 
effects registry of the FDA.
Concerning  efficacy  and  side  effects,  studies 
have  been  limited  to  three  month  follow  ups  with 
statistically  insufficiently  evaluable  data  for  those 
non-blinded phases. More research has to be done to 
provide data on medium and long-term effects even in 
this population with a relatively short life expectancy.
Quality  and  quantity  of  conventional  laxatives 
used as baseline medication and for rescue have not 
been well reported in any of these studies. No study 
has been done so far to compare methylnaltrexone to 
an optimisation of conservative treatment.
conclusion
Subcutaneously applied methylnaltrexone causes lax-
ation in about 50% of patients with advanced illnesses 
and opiate-induced constipation within the first four 
hours after its application. The lack of efficacy on the 
other patients cannot be explained by data available. 
Considering its pharmacokinetic profile and according 
to the studies retrieved, it is safe to apply but strictly 
contraindicated for patients at risk of intestinal per-
foration. It has only been tested against   placebo and 
not been compared against an optimization of other 
laxative treatments. Further research has to be focused 
on  long-term  usage  and  on  patients’  preference 
before one can define its place and economic value 
for patients in a palliative care situation (Table 4).
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